The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of early-onset colorectal cancer on utilization of chemotherapy and outcomes in patients with stage II disease.
 
Jacob Beck Leary
No Relationships to Disclose
 
Junxiao Hu
No Relationships to Disclose
 
Sean Davis
No Relationships to Disclose
 
Alexis Diane Leal
Employment - Elsevier
Leadership - Elsevier
Research Funding - Abbvie (Inst); Arrys Therapeutics (Inst); Bristol-Myers Squibb (Inst); Conjupro Biotherapeutics (Inst); Corcept Therapeutics (Inst); Exelixis (Inst); Hutchison MediPharma (Inst); Takeda (Inst)
 
S. Lindsey Davis
Consulting or Advisory Role - Genentech
Speakers' Bureau - Allergan (I)
Research Funding - AstraZeneca (Inst); Boston Scientific (I); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Halozyme (Inst); I-Mab (Inst); Incyte (Inst); Merck (Inst); OncoMed (Inst); ORIC Pharmaceuticals (Inst); Roche (Inst); Senhwa Biosciences (Inst); Symphogen (Inst)
 
Sunnie S. Kim
Consulting or Advisory Role - Astellas Pharma; Daiichi Sankyo/Lilly
Research Funding - Merck
 
Robert William Lentz
No Relationships to Disclose
 
Tyler Friedrich
No Relationships to Disclose
 
Jon Vogel
No Relationships to Disclose
 
Whitney Herter
No Relationships to Disclose
 
Brandon C. Chapman
No Relationships to Disclose
 
Wells A. Messersmith
Honoraria - Research to Practice (Inst)
Consulting or Advisory Role - Criterium (Inst); Five Prime Therapeutics (Inst); Istari Oncology; QED Therapeutics; Zymeworks
Research Funding - ALX Oncology (Inst); Beigene (Inst); CanBas (Inst); D3 (Inst); Exelixis (Inst); FATE Therapeutics (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); PureTech (Inst); RasCal (Inst)
 
Christopher Hanyoung Lieu
Consulting or Advisory Role - Pfizer (Inst)
Research Funding - Merck (Inst)